Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Authors
Keywords
Relapsing-remitting multiple sclerosis, Disease-modifying therapy, Treatment decisions, Treatment algorithm
Journal
Neurotherapeutics
Volume 13, Issue 1, Pages 47-57
Publisher
Springer Nature
Online
2015-12-23
DOI
10.1007/s13311-015-0412-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
- (2015) Luisa M. Villar et al. ANNALS OF NEUROLOGY
- Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
- (2015) Tomas Kalincik et al. ANNALS OF NEUROLOGY
- Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
- (2015) Pietro Iaffaldano et al. BRAIN
- Novel and imminently emerging treatments in relapsing–remitting multiple sclerosis
- (2015) Jiwon Oh et al. CURRENT OPINION IN NEUROLOGY
- Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis
- (2015) Michele Faulkner Expert Opinion On Drug Safety
- Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
- (2015) Duvyanshu Dubey et al. Expert Review of Neurotherapeutics
- Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
- (2015) Daniela Rau et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- (2015) C McGuigan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Aggressive multiple sclerosis: proposed definition and treatment algorithm
- (2015) Carolina A. Rush et al. Nature Reviews Neurology
- Switching from natalizumab to fingolimod
- (2015) Ludwig Kappos et al. NEUROLOGY
- Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod
- (2015) DeRen Huang NEUROLOGY
- Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial
- (2015) G. L. Mancardi et al. NEUROLOGY
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
- (2015) D. H. Miller et al. NEUROLOGY
- PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
- (2015) Dennis J. Nieuwkamp et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
- (2015) Thorsten Rosenkranz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sphingosine 1-phosphate signaling at the blood–brain barrier
- (2015) Briana Prager et al. TRENDS IN MOLECULAR MEDICINE
- PML: The Dark Side of Immunotherapy in Multiple Sclerosis
- (2015) Clemens Warnke et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
- (2015) Duvyanshu Dubey et al. Expert Review of Neurotherapeutics
- Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
- (2015) Ann M. Arvin et al. JAMA Neurology
- Treatment Decisions for Patients With Active Multiple Sclerosis
- (2015) Olaf Stüve et al. JAMA Neurology
- Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
- (2015) Eva Havrdova et al. Therapeutic Advances in Neurological Disorders
- Alemtuzumab for the treatment of multiple sclerosis
- (2015) Mark Willis et al. Therapeutics and Clinical Risk Management
- No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
- (2014) Richard Nixon et al. ADVANCES IN THERAPY
- Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Clemens Warnke et al. ANNALS OF NEUROLOGY
- Progressive multifocal leukoencephalopathy after natalizumab discontinuation: Few and true?
- (2014) Mike P. Wattjes et al. ANNALS OF NEUROLOGY
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- New management algorithms in multiple sclerosis
- (2014) Per Soelberg Sorensen CURRENT OPINION IN NEUROLOGY
- Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI
- (2014) Mike P. Wattjes et al. CURRENT OPINION IN NEUROLOGY
- Dimethyl fumarate for treating relapsing multiple sclerosis
- (2014) William Sheremata et al. Expert Opinion On Drug Safety
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- (2014) Arianna Sartori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Immunomodulation neuroprotection and remyelination – The fundamental therapeutic effects of glatiramer acetate: A critical review
- (2014) Rina Aharoni JOURNAL OF AUTOIMMUNITY
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
- (2014) Hui Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Natalizumab in clinical practice: managing the risks, enjoying the benefits
- (2014) O. Aktas JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
- (2014) H. Butzkueven et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy
- (2014) Salim Chahin et al. JOURNAL OF NEUROVIROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod
- (2014) Robert Hoepner et al. Multiple Sclerosis Journal
- Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
- (2014) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Alemtuzumab: The advantages and challenges of a novel therapy in MS
- (2014) T. Menge et al. NEUROLOGY
- Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
- (2014) Niklas Bergvall et al. PLoS One
- Disease Activity Free Status
- (2014) Carolyn J. Bevan et al. JAMA Neurology
- Switching From Natalizumab to Fingolimod in Multiple Sclerosis
- (2014) Mikael Cohen et al. JAMA Neurology
- Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
- (2014) Vissia Viglietta et al. Annals of Clinical and Translational Neurology
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Multiple sclerosis: Prospects and promise
- (2013) Stephen L. Hauser et al. ANNALS OF NEUROLOGY
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis
- (2013) Fred D. Lublin et al. ANNALS OF NEUROLOGY
- Progressive multifocal leukoencephalopathy after natalizumab discontinuation
- (2013) Andrew J. Fine et al. ANNALS OF NEUROLOGY
- Progressive multifocal leukoencephalopathy in patients with multiple sclerosis
- (2013) Kelly J. Baldwin et al. CURRENT OPINION IN NEUROLOGY
- Risk evaluation and monitoring in multiple sclerosis therapeutics
- (2013) Michel C Clanet et al. Multiple Sclerosis Journal
- Refining response to treatment as defined by the Modified Rio Score
- (2013) MP Sormani et al. Multiple Sclerosis Journal
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
- (2013) N. Schwab et al. NEUROLOGY
- PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
- (2013) Bob W. van Oosten et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient Treated with Fumaric Acid
- (2013) Ummehan Ermis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
- (2012) Ernst-Wilhelm Radue ARCHIVES OF NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
- (2012) Virginia Devonshire et al. LANCET NEUROLOGY
- Scoring treatment response in patients with relapsing multiple sclerosis
- (2012) MP Sormani et al. Multiple Sclerosis Journal
- Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review
- (2012) E. Lu et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)
- (2012) Niklas Schmedt et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Immune mechanisms of new therapeutic strategies in MS — Teriflunomide
- (2011) Malte C. Claussen et al. CLINICAL IMMUNOLOGY
- Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
- (2011) Jens Ingwersen et al. CLINICAL IMMUNOLOGY
- The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
- (2011) Bernd C. Kieseier CNS DRUGS
- Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model
- (2011) Hye Jung Kim et al. FASEB JOURNAL
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
- (2010) J. W. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Progressive Multifocal Leukoencephalopathy Following Heightened Immunosuppression After Lung Transplant
- (2009) Jesse Waggoner et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- Measures in the first year of therapy predict the response to interferon β in MS
- (2009) J Río et al. Multiple Sclerosis Journal
- The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
- (2009) E. C. Klawiter et al. NEUROLOGY
- Leflunomide-Associated Progressive Multifocal Leukoencephalopathy
- (2008) Megan Rahmlow et al. ARCHIVES OF NEUROLOGY
- FTY720 modulates human oligodendrocyte progenitor process extension and survival
- (2007) Veronique E. Miron et al. ANNALS OF NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation